Cutia Therapeutics (HK:2487) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cutia Therapeutics has reported a remarkable revenue surge of approximately 129.9% for the first nine months of 2024, reaching RMB148.9 million. This growth highlights the strong market performance of its commercialized products, signaling potential opportunities for investors. However, the company advises caution as these figures are based on preliminary unaudited data.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.